{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:46:27Z","timestamp":1767494787440,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470368","81670187"],"award-info":[{"award-number":["81470368","81670187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"crossref","award":["7172047"],"award-info":[{"award-number":["7172047"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2018-1-2151"],"award-info":[{"award-number":["2018-1-2151"]}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"crossref","award":["DFL20151001"],"award-info":[{"award-number":["DFL20151001"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011930","name":"Beijing Medical and Health Foundation","doi-asserted-by":"crossref","award":["2221-16-157"],"award-info":[{"award-number":["2221-16-157"]}],"id":[{"id":"10.13039\/501100011930","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00280-018-3744-z","type":"journal-article","created":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T23:51:49Z","timestamp":1543794709000},"page":"443-449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A retrospective study of the CHOP, CHOPE, and CHOPE\/G regimens as the first-line treatment of peripheral T-cell lymphomas"],"prefix":"10.1007","volume":"83","author":[{"given":"Xuyan","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0367-1411","authenticated-orcid":false,"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"issue":"9844","key":"3744_CR1","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland KR, Armitage JO, Hancock BW (2012) Non-Hodgkin lymphoma. Lancet 380(9844):848\u2013857. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(12)60605-9","journal-title":"Lancet"},{"issue":"6","key":"3744_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1023\/A:1008200307625","volume":"8","author":"S Ascani","year":"1997","unstructured":"Ascani S, Zinzani PL, Gherlinzoni F et al (1997) Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol 8(6):583\u2013592. \n                    https:\/\/doi.org\/10.1023\/A:1008200307625","journal-title":"Ann Oncol"},{"issue":"1","key":"3744_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS et al (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107(1):265\u2013276. \n                    https:\/\/doi.org\/10.1182\/blood-2005-06-2508","journal-title":"Blood"},{"issue":"4","key":"3744_CR4","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.12659","volume":"164","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Matsuda T et al (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 164(4):536\u2013545. \n                    https:\/\/doi.org\/10.1111\/bjh.12659","journal-title":"Br J Haematol"},{"issue":"3","key":"3744_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12185-014-1520-3","volume":"99","author":"S Park","year":"2014","unstructured":"Park S, Ko YH (2014) Peripheral T cell lymphoma in Asia. Int J Hematol 99(3):227\u2013239. \n                    https:\/\/doi.org\/10.1007\/s12185-014-1520-3","journal-title":"Int J Hematol"},{"issue":"20","key":"3744_CR6","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. \n                    https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"25","key":"3744_CR7","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124\u20134130. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.16.4558","journal-title":"J Clin Oncol"},{"key":"3744_CR8","unstructured":"National Comprehensive Cancer Network (2018) Lymphomas T-Cell (Version 5) \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf\n                    \n                  . Accessed 13 Aug 2018"},{"issue":"10","key":"3744_CR9","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstrom J, Jerkeman M et al (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124(10):1570\u20131577. \n                    https:\/\/doi.org\/10.1182\/blood-2014-04-573089","journal-title":"Blood"},{"issue":"18","key":"3744_CR10","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin Lymphoma Study Group. Blood 116(18):3418\u20133425. \n                    https:\/\/doi.org\/10.1182\/blood-2010-02-270785","journal-title":"Blood"},{"issue":"12","key":"3744_CR11","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1093\/annonc\/mdp211","volume":"20","author":"M Nickelsen","year":"2009","unstructured":"Nickelsen M, Ziepert M, Zeynalova S et al (2009) High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German high-grade non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20(12):1977\u20131984. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdp211","journal-title":"Ann Oncol"},{"key":"3744_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escal\u00f3n","year":"2005","unstructured":"Escal\u00f3n MP, Liu NS, Yang Y et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103:2091\u20132098. \n                    https:\/\/doi.org\/10.1002\/cncr.20999","journal-title":"Cancer"},{"key":"3744_CR13","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.3324\/haematol.2015.131151","volume":"101","author":"K Dunleavy","year":"2016","unstructured":"Dunleavy K, Pittaluga S, Shovlin M et al (2016) Phase II trial of dose adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica 101:e27\u2013e29. \n                    https:\/\/doi.org\/10.3324\/haematol.2015.131151","journal-title":"Haematologica"},{"issue":"4","key":"3744_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Venturini F, Stefoni V et al (2010) Gemcitabine as single agent in pretreated T cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21(4):860\u2013863. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdp508","journal-title":"Ann Oncol"},{"issue":"2","key":"3744_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3324\/haematol.10737","volume":"92","author":"HT Arkenau","year":"2007","unstructured":"Arkenau HT, Chong G, Cunningham D et al (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271\u2013272. \n                    https:\/\/doi.org\/10.3324\/haematol.10737","journal-title":"Haematologica"},{"issue":"1","key":"3744_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s12032-012-0351-4","volume":"30","author":"M Dong","year":"2013","unstructured":"Dong M, He XH, Liu P et al (2013) Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma. Med Oncol 30(1):351. \n                    https:\/\/doi.org\/10.1007\/s12032-012-0351-4","journal-title":"Med Oncol"},{"issue":"9","key":"3744_CR17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1080\/10245332.2016.1152084","volume":"21","author":"B Jia","year":"2016","unstructured":"Jia B, Hu S, Yang J et al (2016) Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. Hematology 21(9):536\u2013541. \n                    https:\/\/doi.org\/10.1080\/10245332.2016","journal-title":"Hematology"},{"issue":"1","key":"3744_CR18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","volume":"58","author":"JG Kim","year":"2006","unstructured":"Kim JG, Sohn SK, Chae YS et al (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58(1):35\u201339. \n                    https:\/\/doi.org\/10.1007\/s00280-005-0136-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"3744_CR19","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, Fourth edn. IARC WHO Classification of Tumours, No 2","DOI":"10.1093\/criticalvalues\/2.2.30"},{"issue":"27","key":"3744_CR20","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"1","key":"3744_CR21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T R\u00fcdiger","year":"2002","unstructured":"R\u00fcdiger T, Weisenburger DD, Anderson JR et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin\u2019s Lymphoma Classification Project. Ann Oncol 13(1):140\u2013149. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdf033","journal-title":"Ann Oncol"},{"issue":"5","key":"3744_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3892\/mco.2013.146","volume":"1","author":"W Xie","year":"2013","unstructured":"Xie W, Hu K, Xu F et al (2013) Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: a retrospective analysis of 252 cases. Mol Clin Oncol 1(5):911\u2013917. \n                    https:\/\/doi.org\/10.3892\/mco.2013.146","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"3744_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cncr.27733","volume":"119","author":"D Mahadevan","year":"2013","unstructured":"Mahadevan D, Unger JM, Spier CM et al (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119(2):371\u2013379. \n                    https:\/\/doi.org\/10.1002\/cncr.27733","journal-title":"Cancer"},{"issue":"5","key":"3744_CR24","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/S2352-3026(18)30039-5","volume":"5","author":"M Gleeson","year":"2018","unstructured":"Gleeson M, Peckitt C, To YM et al (2018) CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol 5(5):e190\u2013e200. \n                    https:\/\/doi.org\/10.1016\/S2352-3026(18)30039-5","journal-title":"Lancet Haematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3744-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3744-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3744-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:07:44Z","timestamp":1575313664000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3744-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3744"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3744-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"24 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}